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Several studies have been carried out to clarify the relationship between CD30 expression and Th2 lymphocytes,
although the results have been controversial. To investigate whether CD30 is a useful marker for Th2 lymphocytes
in bronchoalveolar lavage (BAL) in interstitial lung diseases (ILD), we studied six control subjects and 31 patients
with ILD (12 with idiopathic pulmonary fibrosis, seven with hypersensitivity pneumonitis, three with chronic
eosinophilic pneumonia and nine with sarcoidosis). The levels of interleukin-5 (IL-5) (secreted by Th2 cells),
interferon-g (IFNg) (secreted by Th1 cells) and the expression of CD30 on lymphocytes were determined in BAL
fluid. There were no dierences in the percentage of CD30+ lymphocytes between controls and patients with ILD
(08+04% vs. 2+04%). In order to determine the relationship between Th2 cells and CD30 expression, we
divided the patients into two groups according to BAL IL-5 levels. Group 1 consisted of eight patients (three
chronic eosinophilic pneumonia, three hypersensitivity pneumonitis, two idiopathic pulmonary fibrosis) with high
IL-5 levels (298+138 pg ml71). Group II consisted of the remaining 23 ILD patients with normal IL-5 levels
(09+06 pg ml71). The percentage of eosinophils in BAL fluid was significantly higher in group I compared with
group II (34+16% vs. 3+1%, P5005). A correlation between CD30+ lymphocytes and IL-5 in group 1 was not
shown. There were no dierences in the number of CD30+ lymphocytes between both groups (3+1% vs.
18+05%). In group I we found a significant correlation between IL-5 levels and the percentage of eosinophils
(r=095, P500001). Our results suggest that CD30 does not appear to be a useful marker for Th2 lymphocytes in
BAL from patients with ILD.
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Several studies have clearly established that CD4+ T
lymphocytes can be subdivided functionally into two
populations (Th1 and Th2) on the basis of their cytokine
secretion profile (1). Th1 cells produce interleukin (IL)-2,
interferon-g (IFN-g) and tumour necrosis factor-b (TNF-b),
and mediate delayed hypersensitivity reactions, whereas
Th2 lymphocytes produce IL-4, IL-5, IL-6, IL-9 and IL-10
and are involved in humoral immune response. In the
absence of a prominent dierentiation, the large majority of
CD4+T lymphocytes secrete both types of cytokines and
are designated Th0 cells (1). Moreover, CD8+ lymphocytes
can be also subdivided into so-called T1 and T2 popula-
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Th2 cells (2,3). So far, these dierent T cell subtypes have
been characterized by thier cytokine secretion and no clear
correlation with the expression of cell surface antigens has
been established. CD30 is one of the members of the TNF
receptor superfamily that is commonly used as a marker for
Reed–Stenberg cells in Hodgkin’s disease and non-Hodg-
kin’s lymphomas (4). In addition, CD30 is expressed on
activated, but not on resting, human T lymphocytes (5). It
has been reported that the CD30 molecule may be
expressed by blood CD4+ and CD8+ lymphocytes
secreting Th2 type cytokines in vitro, and it has been
proposed as a marker for Th2 cells (3,6). Other studies,
however, have questioned this hypothesis (7). The presence
of a Th1 or Th2 pattern of immune response in interstitial
lung diseases has only been investigated in a few studies (8–
12). To our knowledge, however, the usefulness of CD30 as
a marker of Th2 cells in interstitial lung disease has not
been previously evaluated. The objective of this study was
to investigate whether CD30 is a marker for Th2 cells in
interstitial lung diseases. To do this, we have determined the
expression of CD30 on BAL cells and their relationship
with BAL fluid levels of IL-5 (secreted by Th2 cells) and# 2000 HARCOURT PUBLISHERS LTD
346 D. PETKOVA ET AL.INFg (secreted by Th1 cells) in patients with various
interstitial lung diseases.
Material and methods
STUDY SUBJECTS
Control group
Six subjects (age 422+66 years, mean+SE) who were not
taking any medication, had no history of diuse respiratory
diseases, an absence of respiratory infections in the previous
3 months, a negative prick test and normal pulmonary
function tests, were included. Two of them were smokers.
Fiberoptic bronchoscopy was performed in the event of an
episode of haemoptysis with normal chest X-ray, isolated
pulmonary node, or suspicion of upper airway disease.
Bronchoscopy was macroscopically normal in all patients
with negative microbiological and cytological analyses of
bronchial washings.
Interstitial lung disease
We studied 31 untreated patients (age 58+4 years) with
interstitial lung disease: nine with sarcoidosis, 12 with
idiopathic pulmonary fibrosis, seven with hypersensitivity
pneumonitis and three with chronic eosinophillic pneumo-
nia. The diagnosis of sarcoidosis was established by
compatible clinical criteria, chest roentgenogram, bronch-
oalveolar lavage findings and the presence of non-caseating
epitheloid cell granulomas on transbronchial lung biopsy
and/or skin biopsy. According to chest X-ray findings, eight
patients had stage I disease and one had stage II disease. All
patients with stage I disease had normal pulmonary
function tests. The diagnosis of idiopathic pulmonary
fibrosis was established by clinical and radiographic criteria
and high resolution computed tomographic (CT) scan
findings, and was confirmed by open lung biopsy in five
patients. The diagnosis of hypersensitivity pneumonitis was
made on the basis of documented history of exposure to
aetiological antigens, clinical features, fiberoptic broncho-
scopy findings (transbronchial biopsy and/or bronchoal-
veolar lavage) and serum antibodies and skin tests positive
against antigens. All patients had a pigeon breeder disease.
Chronic eosinophillic pneumonia was diagnosed by clinical
and radiographic data, and bronchoalveolar lavage and
transbronchial biopsy findings. In these patients, there was
no known cause of hypereosinophilla (drugs, parasitic
infections, fungal disease). None of the patients with ILD
had clinical and pulmonary functional manifestations of
asthma or rhinitis. The study was approved by the Ethics
Committee of the Hospital Clinic.
BRONCHOALVEOLAR LAVAGE
Bronchoalveolar lavage, as well as the total cell count, cell
viability and dierential cell counts, was performed as
previously described (13,14). The supernatant obtainedafter centrifugation of BAL fluid was stored at7708C until
used. The staining of BAL cells with monoclonal antibodies
was carried out using the immunoalkaline phosphatase
method (15). The following monoclonal antibodies were
used: CD30 (Ki-antigen, clone Ber-H2, Dako patts,
Glostrup, Denmark) and Leu 4, Leu 3a and Leu 2a (Becton
Dickinson, Mountain View, CA, U.S.A.), which recognize
T lymphocytes (CD3), T helper/inducer cells (CD4) and T
supressor/cytotoxic cells (CD8), respectively. The negative
control of the immunocytochemical reaction was carried out
by incubating the cell smears with all reagents except the
monoclonal antibody and replacing it with normal mouse
serum. Two hundred lymphocytes from each reaction were
counted by light micorscopy (61000), and the percentage of
positive cells was calculated. The concentration of IL-5 and
IFN-g was measured in unconcentrated BAL fluids with
commercial ELISA kits from immunotech (IL-5) and Bender
Medical System (IFN-g) using a sandwich technique.
STATISTICAL ANALYSIS
Results are expressed as means+SE. Wilcoxon’s test was
used for comparison of paired data and Mann–Whitney U-
test for unpaired data. Spearman’s correlation coecients
were used for correlation analysis when appropriate. The
statistical significance was established when a P-value was
equal to or lower than 005.
Results
BRONCHOALVEOLAR LAVAGE FLUID
CELL ANALYSIS
The characteristics of BAL cell analysis are represented in
Table 1. Total cell counts were significantly higher in
patients with chronic eosinophilic pneumonia with respect
to the other groups. The percentage of eosinophils was
significantly increased in BAL fluid from idiopathic
pulmonary fibrosis, hypersensitivity pneumonitis and
chronic eosinophilic pneumonia. Patients with chronic
eosinophilic pneumonia had the highest eosinophilia
(480%). The percentage of lymphocytes in patients with
hypersensitivity pneumonitis and sarcoidosis was signifi-
cantly higher in comparison with the controls. Moreover,
we found a significant dierence in the percentage of
neutrophils in idiopathic pulmonary fibrosis and hypersen-
sitivity pneumonitis with respect to controls. Lymphocyte
subset analysis showed that the CD4+/CD8+ lymphocytes
ration was significantly increased in sarcoidosis and decreased
in hypersensitivity pneumonitis, in comparison with the other
groups. Immunocytochemical analysis with CD30 mono-
clonal antibody showed that only lymphocytes were stained.
However, we did not find any dierence in the percentage of
CD30+ lymphocytes in any of the groups studied.
CYTOKINE LEVELS IN BAL FLUID
The concentration of IL-5 in BAL fluid was significantly
higher in patients with interstitial lung diseases with respect
TABLE 1. Bronchoalveolar lavage characteristics of the population studied
Controls
(n=6)
IPF
(n=12)
HP
(n=7)
CEP
(n=3)
S
(n=9)
Volume recovered (ml) 60+5 52+8 46+6 57+6 68+11
Total cells (6104 ml71) 37+8 101+38 49+11 716+223* 38+6
Cell viability (%) 79+5 74+3 88+5 98+1 81+3
Macrophages (%) 92+2 81+3* 62+5* 6+4* 81+4*
Lymphocytes (%) 7+2 10+2 21+4* 4+2 18+3*
Neutrophils (%) 1+04 6+1* 14+5* 1+03 1+04
Eosinophils (%) 0 4+1* 4+2* 88+4* 0
Lymphocytes CD3+ (%) 63+02 60+7 73+6* 72+9* 60+7
Lymphocytes CD4+ (%) 49+01 35+6 24+6 56+14* 41+5*
Lymphocytes CD8+ (%) 29+02 31+4 54+10* 32+10 20+4
CD4+/CD8+ ratio 16+01 15+04 05+01* 12+01 3+1*
Lymphocytes CD30+ (%) 08+04 2+1 06+03 2+05 4+2
IPF: idiopathic pulmonary fibrosis; HP: hypersensitivity pneumonitis; CEP: chronic eosinophilic pneumonia; S: sarcoidosis.
*significantly dierent compared with controls (P5005).
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tively, P5005). In contrast, there were no dierences in
IFNg levels between controls (05+04 pg ml71) and
interstitial lung diseases (08+0.3 pg ml71). In order to
clarify the relationship between CD30+lymphocytes and
Th2 cells we divided the patients with interstitial lung
diseases into two groups, according to the concentration of
IL-5, the cytokine produced by Th2 cells (Table 2). Group I
consisted of eight patients (three patients with chronic
eosinophilic pneumonia, three with hypersensitivity pneu-
monitis and two with idiopathic pulmonary fibrosis) with
high levels of BAL IL-5 (higher than mean+2 SD IL-5 level
in the control group). Group II consisted of the remaining
23 patients (four with hypersensitivity pneumonitis, 10 with
idiopathic pulmonary fibrosis and nine with sarcoidosis)
with normal IL-5 levels. The percentage and absolute
numbers of eosinophils were significantly higher in group I
with respect to group II (34+16% vs. 3+1%, and
243+1386104 ml71 vs. 27+126104 ml71, respectively,
P5005). In group I, BAL IL-5 concentration correlated
significantly with both the percentages and absolute
numbers of eosinophils (r=095; P=00001) (Fig. 1).
However, we did not find any correlation between the
CD30+ lymphocytes (percentage and absolute number)
and IL-5 concentration in the same group. In addition,
there were no dierences in CD30+ cells between group I
and II. We did not find any dierences in the levels of BAL
IFN-g between the two groups.
Discussion
The main finding of our study was that CD30 does not
appear to be a useful marker for Th2 lymphocytes in BAL
in interstitial lung diseases, as shown by the lack of
relationship between the levels of IL-5, secreted predomi-
nantly by Th2 cells, and the number of lymphocytes
CD30+.The usefulness of CD30 as a marker of Th2 cells has been
investigated in several studies with controversial results.
Del Prete et al. (6) reported that blood T cell clones with
established Th2 profiles of cytokine secretion expressed
CD30 in vitro, while Th1 clones showed low or undetectable
expression of this molecule. In contrast, other studies (7,16)
have demonstrated that CD30 can be expressed in vitro by
activated T cells of Th0, Th1 or Th2 subtypes. In vivo
studies have shown a lack of CD30+ cells in bronchial
biopsies from patients with asthma, a disease characterized
by a Th2 inflammatory response (17). In addition, Agostini
et al. showed that BAL lymphocytes from patients with
hypersensitivity pneumonitis, a disease preferentially asso-
ciated with the production of Th-2 cytokines, do not
express CD30 (18). Moreover, the results of our study agree
with those of Agostini et al. as the number of BAL CD30+
lymphocytes are similar in both normal subjects and
patients with interstitial lung diseases. Thus, these findings
suggest that CD30 may not represent an operational Th2
maker in vivo.
The distribution and significance of Th1/Th2 lympho-
cytes in interstitial lung diseases has only been investigated
in a few studies. Walker et al. (8) determined the cytokine
levels in BAL fluid of patients with various interstitial lung
diseases and found that sarcoidosis is the only disease
characterized by a Th1 cell cytokine profile. In contrast,
chronic eosinophilic pneumonia, idiopathic pulmonary
fibrosis and hypersensitivity pneumonitis showed a cyto-
kine pattern incompatible with a pure Th1 or Th2 cell
response, because IL-5, IL-2 and IFNg were found at
increased levels. However, a predominance of a Th2
inflammatory response has been observed in the pulmonary
interstitium of patients with idiopathic pulmonary fibrosis
(11,12). In addition, other studies have confirmed that only
Th1 lymphocytes are activated at the sites of inflammation
and granuloma formation in sarcoidosis (9,19).
In the present study, we have determined the BAL levels
of IL-5 (secreted by Th2 cells) and IFNg (secreted by Th1
TABLE 2. Cytokine levels and CD30 lymphocyte expression in BAL fluid
Controls
(n=6)
GROUP I
(n=8)
GROUP II
(n=23)
IL-5 (pg ml71) 09+06 298+138*,{ 07+02
INF-g (pg ml71) 05+04 17+1 05+01
Lymphocytes (%) 7+2 9+3 16+2
Lymphocytes (6104 ml71) 3+11 16+9 9+2
Lymphocytes CD30+ (%) 08+04 3+1 18+05
Lymphocytes CD30+ (6104 ml71) 002+001 02+11 01+01
Eosinophils (%) 0 34+16*,{ 3+1
Eosinophils (6104 ml71) 0 243+138*,{ 27+12
Group I: Interstitial lung diseases with high IL-5 BAL levels. Group II: Interstitial lung diseases with normal IL-5 BAL levels.
*significantly dierent from controls; {significantly dierent between groups I and II (P5005).
FIG 1. Correlation between the levels of IL-5 and the
percentage of eosinophils in bronchoalveolar lavage in
patients from group I (r=095; P=00001).
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patients with interstitial lung diseases with respect to the
controls, while no dierences were shown in IFNg
concentration. The low levels of IFNg in sarcoidosis may
be explained by the low activity of the disease, as eight out
of nine patients presented chest X-ray stage I and normal
pulmonary function tests in the absence of respiratory
symptoms. Moreover, it has been suggested that the
concentration of IFNg produced by T cell clones from
BAL fluid may be similar in sarcoidosis and normal
subjects (10).
In order to determine the usefulness of CD30 as a marker
of Th2 cells, we divided the patients with interstitial lung
diseases into two groups according to the levels of BAL IL-
5. High levels of IL-5 were found in patients with
hypersensitivity pneumonitis, idiopathic pulmonary fibrosis
and chronic eosinophilic pneumonia. In contrast, all
patients with sarcoidosis, characterized by a Th1 inflam-
matory response, had a normal concentration of IL-5 in
BAL. In the group of patients with raised levels of IL-5 we
did not find a relationship between the levels of this
cytokine and the number of CD30+ lymphocytes. This
finding indicates that CD30 does not appear to be a markerfor Th2 cells. One possible limitation on the interpretation
of these findings is the fact that the analysis of cytokines
present in BAL fluid does not allow for any definite
conclusions about the cell type responsible for their
production. In this respect, it has been demonstrated that
mast cells can secrete a Th2-like cytokine pattern (20) and
eosinophils are capable of IL-5 secretion (21). Furthermore,
interstitial cells in the pulmonary interstitium, inaccessible
to BAL may secrete cytokines to the alveolar lining fluid.
However, it has been shown that activated T cells are the
main source of Th2-like cytokines (22,23).
Our study also showed a strong relationship between the
number of BAL eosinophils and IL-5 levels. This finding
has been previously reported and provides evidence that IL-
5 has a predominant role in the recruitment of eosinophils
in interstitial lung diseases (8). Activated T cells are thought
to be the main source of the cytokines which regulate the
activation and migration of eosinophils. In this respect, a
strong relationship has been demonstrated between the
number of activated T cells and the number of eosinophils
in BAL from patients with various interstitial lung diseases
(8,24). Unfortunately, we did not investigate the markers of
T cell activation. In our study however, patients with
chronic eosiniphilic pneumonia had the highest percentages
of eosinophils and IL-5 levels in BAL. Thus, eosinophils
may be the source of part of the IL-5 found in BAL fluid. In
any case, both the results obtained in these studies and our
findings suggest that cytokines secreted by the Th2 cells
regulate the recruitment of eosinophils, and this reinforces
our observation that CD30 is not a useful marker for these
cells. In conclusion, our study suggest that CD30 does not
appear to be a useful marker of Th2 in BAL from patients
with interstitial lung diseases.
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